Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs

The Japanese pharmaceutical market suffered a “triple whammy” in the first half of FY2014 due to inroads by generic drugs, NHI price reductions, and the repercussions from a sale tax hike in April. Actually, however, there was another special factor...read more